Literature DB >> 15360011

Aggressive natural killer cell leukemia/lymphoma: case report, use of telesynergy and review of the literature.

Joanne Murdock1, Elaine S Jaffe, Wyndham H Wilson, Damian T McManus, H Denis Alexander, T C M Curly Morris.   

Abstract

Natural killer cell malignancies, although increasingly recognized, remain rare tumors within the USA and Europe. They are somewhat more common in Asia, and have been best characterized within this population. We present a case of a young Caucasian woman who presented acutely with an aggressive natural killer cell leukemia/lymphoma. Use of Telesynergy technology enabled a transatlantic telemedicine conference with colleagues in a center of expertise. Unfortunately the patient was ultimately refractory to both conventional chemotherapy and Campath-1H and her disease course was fulminant, as has been described previously in this condition. We review the possible therapeutic options for this extremely aggressive malignancy and briefly discuss our center's experience of telemedicine technology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15360011     DOI: 10.1080/10428190310001646879

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  5 in total

Review 1.  Acute liver failure due to natural killer-like T-cell leukemia/lymphoma: a case report and review of the literature.

Authors:  Evan S Dellon; Shannon R Morris; Wozhan Tang; Cherie H Dunphy; Mark W Russo
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

2.  A multi-institutional mobility model for regional deployment of Telesynergy telemedicine systems.

Authors:  Larry L Schenken; Dwight E Heron; Cheng B Saw; Julian W Proctor
Journal:  J Telemed Telecare       Date:  2009       Impact factor: 6.184

3.  Six cases of aggressive natural killer-cell leukemia in a Chinese population.

Authors:  Qiguo Zhang; Wang Jing; Jian Ouyang; Hui Zeng; Suraj K George; Zhiqiang Liu
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

4.  The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms.

Authors:  Jew Win Kuan; Kian Meng Chang; Ngee Siang Lau; Purushothaman Visalachy; Sen Mui Tan; Tee Chuan Ong; Anselm Ting Su
Journal:  Indian J Hematol Blood Transfus       Date:  2011-06-05       Impact factor: 0.900

Review 5.  Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis.

Authors:  Margarida Lima
Journal:  Orphanet J Rare Dis       Date:  2013-07-01       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.